Navigation Links
Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
Date:4/6/2011

were treated with placebo (p=0.020).  A reduction in the risk of preterm birth was observed in both women with and without a prior history of preterm birth.  PROCHIEVE was also associated with a significant reduction in the risk of preterm birth before 28 and 35 weeks gestation (p=0.036 and 0.016, respectively).

Neonatal Infant SafetyNeonatal safety outcomes were also evaluated for PROCHIEVE as compared to placebo. Incidences of neonatal morbidity, respiratory distress syndrome, bronchopulmonary dysplasia, grade III or IV intraventricular hemorrhage, periventricular leukomalacia, proven sepsis, necrotizing enterocolitis and perinatal mortality (fetal death or neonatal death) were measured.  Four composite outcome scores were also used to assess prenatal mortality and neonatal morbidity.  Data showed strong trends favoring PROCHIEVE.

PROCHIEVE was well tolerated in the trial.  Adverse events were comparable between women who received PROCHIEVE and those who received placebo.  The most frequently reported adverse events related to study treatment occurred in 2% of women and included vaginal pruritus, vaginal discharge, vaginal candidiasis and nausea. Furthermore, no fetal or neonatal safety signal was detected for women treated with PROCHIEVE.

This study was conducted in collaboration with the Perinatology Research Branch (PRB) of the Division of Intramural Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH).

About Preterm BirthOccurring in one in eight live births, preterm birth is a leading cause of perinatal morbidity and mortality worldwide and its prevention is an important healthcare priority. The economic impact of preterm birth is significant, costing more than $26 billion annually, with the average preterm infant costing approximately $52,000.

The newborn complications associated with p
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.; Columbia Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
4. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
5. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
6. HealthWarehouse.com Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State
7. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
8. Columbia Laboratories to Discuss Fourth Quarter and Year End 2010 Financial Results on March 10, 2011, Conference Call
9. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
10. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
11. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... 19, 2011 Families of Spinal Muscular Atrophy announced today ... and Drug Administration to commence a Phase I safety study ... being developed for Spinal Muscular Atrophy. FSMA ... stages of drug development, when risk is the highest.  It ...
... PRNewswire / -- Silicon Valley Bank ... companies worldwide, released a study today that ... capital-backed biotech and medical device companies. Based ... of US venture-capital backed companies (60 biotech and 58 ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 2Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 3Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 2Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 3
(Date:7/30/2014)... Hamilton Facial Plastic Surgery is happy ... on July 30th. After months of planning, Dr. Hamilton ... state-of-the-art suite, located only steps away from the original ... one-on-one patient comfort, shorter wait times, and generally a ... new office-suite will continue to provide the same wide ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 DRE Medical ... to announce the launch of its Medical Trade ... resource for medical professionals and equipment vendors. , The ... and conventions in the United States and around the ... calendar, and that number is always growing. , Information ...
(Date:7/30/2014)... The Technology Association of Georgia in ... (B&TA), today issued its final call for applications and ... companies have until August 29th 2014 to be considered ... selected by the Excalibur Judging Committee. Companies selected as ... judges for interviewing process. , The TAG Excalibur ...
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help consumers ... Quote tool on its website, LTCconsumer.com , announced Nathan ... free and unlimited. , The Instant Quote tool ... age, gender, and state of residence – and delivers a ... enter any contact information to get started). There is no ...
(Date:7/30/2014)... Detroit, MI (PRWEB) July 30, 2014 ... community to celebrate Safety Day from 4 p.m. to ... in Livonia (29580 7 Mile Road, Livonia, MI 48152). ... DeKeyser, free bike helmets, children’s activities, music, snacks and ... for $299,497 to the Children’s Hospital of Michigan Foundation. ...
Breaking Medicine News(10 mins):Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... ... it experiences a significant increase in calls in 2009 , ... Belleville, Ill. (Vocus) July 26, 2009 -- Allsup has awarded ... national nonprofit organization,s Information HelpLine, which is experiencing a dramatic increase in calls from individuals ...
... KIGALI, Rwanda (July 27, 2009) Government health officials ... for accreditation of the continent,s medical laboratories, starting a ... U.S. Government believe will be an historic step to ... patients. Just a handful of Africa,s laboratories are ...
... but long-term use raises concerns , SUNDAY, July 26 ... be given to children apparently depends on who you ... have recommended that obese children as young as 8 ... lifestyle changes don,t improve their health. , , But ...
... , , WASHINGTON, July 25 ... Landrieu today made the following comment on the release of the ... on Small Businesses and Their Employees" report: , ... to address concerns of small businesses and healthcare -- the number ...
... 24 Duane Reade Holdings, Inc. announced today that its ... "Issuers"), have amended the terms of their previously announced offers ... Notes due 2010 (the "Floating Rate Notes") (the "FRN Offer") ... "Subordinated Notes" and, together with the Floating Rate Notes, the ...
... could speed repair of ligaments, tendons, study shows , FRIDAY, ... University undergraduates say they have found a way to quickly ... a procedure they believe may help improve healing and prevent ... procedure as part of a contest sponsored by a medical ...
Cached Medicine News:Health News:Allsup Awards Grant to National Alliance on Mental Illness 2Health News:Allsup Awards Grant to National Alliance on Mental Illness 3Health News:Leading health organizations launch new accreditation process for laboratories across Africa 2Health News:Leading health organizations launch new accreditation process for laboratories across Africa 3Health News:Leading health organizations launch new accreditation process for laboratories across Africa 4Health News:Giving Statins to Kids Provokes Debate 2Health News:Giving Statins to Kids Provokes Debate 3Health News:Duane Reade Holdings, Inc. Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes 2Health News:Duane Reade Holdings, Inc. Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes 3Health News:Duane Reade Holdings, Inc. Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes 4Health News:Duane Reade Holdings, Inc. Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes 5Health News:Coming Soon -- Stem-Cell Surgical Thread? 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: